The natural compound periplogenin suppresses the growth of prostate carcinoma cells by directly targeting ATP1A1
Natural compounds constitute a major resource for the development of medicines for multiple diseases. While many natural compounds show strong biological activity, the mechanisms that confer clinical benefits are often elusive and have been attributed to multiple pathways. Periplogenin (PPG), a natu...
Uloženo v:
| Vydáno v: | Scientific reports Ročník 14; číslo 1; s. 20509 - 8 |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
03.09.2024
Nature Publishing Group Nature Portfolio |
| Témata: | |
| ISSN: | 2045-2322, 2045-2322 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Natural compounds constitute a major resource for the development of medicines for multiple diseases. While many natural compounds show strong biological activity, the mechanisms that confer clinical benefits are often elusive and have been attributed to multiple pathways. Periplogenin (PPG), a natural compound isolated from
Cortex periplocae
, exhibits strong anti-tumor activities in several human cancer cell lines. However, its molecular mode of action remained unclear. In this study, we leveraged a forward genetic screening approach in DU145 prostate cancer cells to uncover the molecular target of PPG using chemical mutagenesis. Next generation sequencing revealed that a single amino acid substitution at amino acid 804 in ATP1A1 (ATPase Na + /K + Transporting Subunit Alpha 1) confers resistance to the cytotoxic activity of PPG. Mechanistically, ATP1A1 T804 forms a hydrogen bond with PPG which is abolished by the T804A substitution in ATP1A1, resulting in resistance to PPG treatment in vitro. Importantly, in vivo, PPG strongly suppressed tumor development in a DU145 xenograft model whereas DU145 xenograft tumors carrying a
ATP1A1-T804A
mutation were largely unaffected by the treatment. These findings demonstrate that PPG suppresses the growth of DU145 prostate cancer cells in vitro and in vivo by directly binding to ATP1A1 and highlight the power of our unbiased forward genetic screening approach to uncover direct drug target structures at single amino acid resolution. |
|---|---|
| AbstractList | Natural compounds constitute a major resource for the development of medicines for multiple diseases. While many natural compounds show strong biological activity, the mechanisms that confer clinical benefits are often elusive and have been attributed to multiple pathways. Periplogenin (PPG), a natural compound isolated from
Cortex periplocae
, exhibits strong anti-tumor activities in several human cancer cell lines. However, its molecular mode of action remained unclear. In this study, we leveraged a forward genetic screening approach in DU145 prostate cancer cells to uncover the molecular target of PPG using chemical mutagenesis. Next generation sequencing revealed that a single amino acid substitution at amino acid 804 in ATP1A1 (ATPase Na + /K + Transporting Subunit Alpha 1) confers resistance to the cytotoxic activity of PPG. Mechanistically, ATP1A1 T804 forms a hydrogen bond with PPG which is abolished by the T804A substitution in ATP1A1, resulting in resistance to PPG treatment in vitro. Importantly, in vivo, PPG strongly suppressed tumor development in a DU145 xenograft model whereas DU145 xenograft tumors carrying a
ATP1A1-T804A
mutation were largely unaffected by the treatment. These findings demonstrate that PPG suppresses the growth of DU145 prostate cancer cells in vitro and in vivo by directly binding to ATP1A1 and highlight the power of our unbiased forward genetic screening approach to uncover direct drug target structures at single amino acid resolution. Natural compounds constitute a major resource for the development of medicines for multiple diseases. While many natural compounds show strong biological activity, the mechanisms that confer clinical benefits are often elusive and have been attributed to multiple pathways. Periplogenin (PPG), a natural compound isolated from Cortex periplocae, exhibits strong anti-tumor activities in several human cancer cell lines. However, its molecular mode of action remained unclear. In this study, we leveraged a forward genetic screening approach in DU145 prostate cancer cells to uncover the molecular target of PPG using chemical mutagenesis. Next generation sequencing revealed that a single amino acid substitution at amino acid 804 in ATP1A1 (ATPase Na + /K + Transporting Subunit Alpha 1) confers resistance to the cytotoxic activity of PPG. Mechanistically, ATP1A1 T804 forms a hydrogen bond with PPG which is abolished by the T804A substitution in ATP1A1, resulting in resistance to PPG treatment in vitro. Importantly, in vivo, PPG strongly suppressed tumor development in a DU145 xenograft model whereas DU145 xenograft tumors carrying a ATP1A1-T804A mutation were largely unaffected by the treatment. These findings demonstrate that PPG suppresses the growth of DU145 prostate cancer cells in vitro and in vivo by directly binding to ATP1A1 and highlight the power of our unbiased forward genetic screening approach to uncover direct drug target structures at single amino acid resolution. Natural compounds constitute a major resource for the development of medicines for multiple diseases. While many natural compounds show strong biological activity, the mechanisms that confer clinical benefits are often elusive and have been attributed to multiple pathways. Periplogenin (PPG), a natural compound isolated from Cortex periplocae, exhibits strong anti-tumor activities in several human cancer cell lines. However, its molecular mode of action remained unclear. In this study, we leveraged a forward genetic screening approach in DU145 prostate cancer cells to uncover the molecular target of PPG using chemical mutagenesis. Next generation sequencing revealed that a single amino acid substitution at amino acid 804 in ATP1A1 (ATPase Na + /K + Transporting Subunit Alpha 1) confers resistance to the cytotoxic activity of PPG. Mechanistically, ATP1A1 T804 forms a hydrogen bond with PPG which is abolished by the T804A substitution in ATP1A1, resulting in resistance to PPG treatment in vitro. Importantly, in vivo, PPG strongly suppressed tumor development in a DU145 xenograft model whereas DU145 xenograft tumors carrying a ATP1A1-T804A mutation were largely unaffected by the treatment. These findings demonstrate that PPG suppresses the growth of DU145 prostate cancer cells in vitro and in vivo by directly binding to ATP1A1 and highlight the power of our unbiased forward genetic screening approach to uncover direct drug target structures at single amino acid resolution.Natural compounds constitute a major resource for the development of medicines for multiple diseases. While many natural compounds show strong biological activity, the mechanisms that confer clinical benefits are often elusive and have been attributed to multiple pathways. Periplogenin (PPG), a natural compound isolated from Cortex periplocae, exhibits strong anti-tumor activities in several human cancer cell lines. However, its molecular mode of action remained unclear. In this study, we leveraged a forward genetic screening approach in DU145 prostate cancer cells to uncover the molecular target of PPG using chemical mutagenesis. Next generation sequencing revealed that a single amino acid substitution at amino acid 804 in ATP1A1 (ATPase Na + /K + Transporting Subunit Alpha 1) confers resistance to the cytotoxic activity of PPG. Mechanistically, ATP1A1 T804 forms a hydrogen bond with PPG which is abolished by the T804A substitution in ATP1A1, resulting in resistance to PPG treatment in vitro. Importantly, in vivo, PPG strongly suppressed tumor development in a DU145 xenograft model whereas DU145 xenograft tumors carrying a ATP1A1-T804A mutation were largely unaffected by the treatment. These findings demonstrate that PPG suppresses the growth of DU145 prostate cancer cells in vitro and in vivo by directly binding to ATP1A1 and highlight the power of our unbiased forward genetic screening approach to uncover direct drug target structures at single amino acid resolution. Abstract Natural compounds constitute a major resource for the development of medicines for multiple diseases. While many natural compounds show strong biological activity, the mechanisms that confer clinical benefits are often elusive and have been attributed to multiple pathways. Periplogenin (PPG), a natural compound isolated from Cortex periplocae, exhibits strong anti-tumor activities in several human cancer cell lines. However, its molecular mode of action remained unclear. In this study, we leveraged a forward genetic screening approach in DU145 prostate cancer cells to uncover the molecular target of PPG using chemical mutagenesis. Next generation sequencing revealed that a single amino acid substitution at amino acid 804 in ATP1A1 (ATPase Na + /K + Transporting Subunit Alpha 1) confers resistance to the cytotoxic activity of PPG. Mechanistically, ATP1A1 T804 forms a hydrogen bond with PPG which is abolished by the T804A substitution in ATP1A1, resulting in resistance to PPG treatment in vitro. Importantly, in vivo, PPG strongly suppressed tumor development in a DU145 xenograft model whereas DU145 xenograft tumors carrying a ATP1A1-T804A mutation were largely unaffected by the treatment. These findings demonstrate that PPG suppresses the growth of DU145 prostate cancer cells in vitro and in vivo by directly binding to ATP1A1 and highlight the power of our unbiased forward genetic screening approach to uncover direct drug target structures at single amino acid resolution. |
| ArticleNumber | 20509 |
| Author | Zhang, Liqun Zhang, Haifeng Michlits, Georg Pang, Tinglin Horn, Moritz Dyczynski, Matheus Zhang, Xinquan |
| Author_xml | – sequence: 1 givenname: Xinquan surname: Zhang fullname: Zhang, Xinquan organization: Angal Biotechnology Co., Ltd., Life Health Town, National High-Tech Development Zone – sequence: 2 givenname: Tinglin surname: Pang fullname: Pang, Tinglin organization: Angal Biotechnology Co., Ltd., Life Health Town, National High-Tech Development Zone – sequence: 3 givenname: Haifeng surname: Zhang fullname: Zhang, Haifeng organization: Angal Biotechnology Co., Ltd., Life Health Town, National High-Tech Development Zone – sequence: 4 givenname: Moritz surname: Horn fullname: Horn, Moritz organization: JLP Health GmbH – sequence: 5 givenname: Georg surname: Michlits fullname: Michlits, Georg organization: JLP Health GmbH – sequence: 6 givenname: Matheus surname: Dyczynski fullname: Dyczynski, Matheus email: Matheus.dyczynski@angalbio.com organization: JLP Health GmbH – sequence: 7 givenname: Liqun surname: Zhang fullname: Zhang, Liqun email: Liqun.Zhang@angalbio.com organization: Angal Biotechnology Co., Ltd., Life Health Town, National High-Tech Development Zone |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39227746$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1v1DAUjFARLaV_gAOyxIVLIP6KkxNaVbRUqgSH5Ww59kvWq8QOtlO0_x7vbiltD_XFlj0zfu_NvC1OnHdQFO9x9RlXtPkSGeZtU1aElQILQkrxqjgjFeMloYScPDqfFhcxbqu8OGkZbt8Up7QlRAhWnxXzegPIqbQENSLtp9kvzqAZgp1HP4CzDsVlngPECBGlDB6C_5M2yPdoDj4mlQBpFbR1flJIwzhG1O2QsQF0GncoqTBAsm5Aq_VPvMLvite9GiNc3O_nxa-rb-vL7-Xtj-uby9VtqTnDqWTAOTZcC85Y1eFOEG0Uq6kwgivFeq1FazrSaUI4o7XWuTlhakOAs0YoRc-Lm6Ou8Wor52AnFXbSKysPFz4MUoVk9QhSGBAt6wxWtGJ1YxRvRFdXTatainujs9bXo9a8dBMYDS7lcT0Rffri7EYO_k5iTAXBtMoKn-4Vgv-9QExysnE_LOXAL1FSnN2psWjqDP34DLr1S3B5VgcUrRkTe9SHxyU91PLP2QwgR4DOLsUA_QMEV3KfIHlMkMwJkocESZFJzTOSttlh6_dt2fFlKj1SY_7HDRD-l_0C6y-bZds3 |
| CitedBy_id | crossref_primary_10_1016_j_bioorg_2025_108396 |
| Cites_doi | 10.1007/s10549-005-9053-3 10.1016/S0021-9258(17)32067-7 10.1091/mbc.e04-03-0222 10.1128/mbio.03349-22 10.4065/82.2.243 10.3390/molecules26071905 10.18632/oncotarget.24305 10.1166/jbn.2020.2978 10.1161/HYPERTENSIONAHA.113.01733 10.1530/ERC-13-0466 10.1186/s12014-017-9150-4 10.2174/1871520620666200708104559 10.12688/f1000research.10481.1 10.1152/ajpcell.00359.2015 10.1016/j.phymed.2018.10.008 10.1007/s10863-007-9107-9 10.1016/j.ijpharm.2016.02.024 10.1055/s-0029-1240600 10.3390/nu12030679 10.1016/j.virusres.2016.11.028 10.1038/nprot.2013.143 10.3390/ijms222010981 10.1038/s41388-021-01817-2 10.1016/S0014-5793(04)00292-3 10.1016/j.bcp.2016.02.001 10.1007/s11101-014-9367-z 10.1124/mi.3.3.157 10.1016/j.eururo.2009.06.027 10.1016/j.coph.2008.07.005 10.1371/journal.pone.0153723 10.21037/amj.2018.12.07 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-024-71722-7 |
| DatabaseName | Springer Nature OA/Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_7de794bd1a30468da587b6089a931fdc PMC11372130 39227746 10_1038_s41598_024_71722_7 |
| Genre | Journal Article |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD AFPKN CITATION PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c541t-4e551d5c75440b1b72cda4637d75aa4fcc79db2bc225436cc0527d6d2e5487aa3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 2 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001305757100017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2045-2322 |
| IngestDate | Tue Oct 14 19:06:43 EDT 2025 Tue Nov 04 02:05:01 EST 2025 Fri Sep 05 14:48:45 EDT 2025 Tue Oct 07 09:10:40 EDT 2025 Wed Feb 19 02:07:38 EST 2025 Tue Nov 18 22:49:44 EST 2025 Sat Nov 29 05:24:07 EST 2025 Fri Feb 21 02:38:05 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-4e551d5c75440b1b72cda4637d75aa4fcc79db2bc225436cc0527d6d2e5487aa3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/7de794bd1a30468da587b6089a931fdc |
| PMID | 39227746 |
| PQID | 3100364476 |
| PQPubID | 2041939 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7de794bd1a30468da587b6089a931fdc pubmedcentral_primary_oai_pubmedcentral_nih_gov_11372130 proquest_miscellaneous_3100561786 proquest_journals_3100364476 pubmed_primary_39227746 crossref_primary_10_1038_s41598_024_71722_7 crossref_citationtrail_10_1038_s41598_024_71722_7 springer_journals_10_1038_s41598_024_71722_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-09-03 |
| PublicationDateYYYYMMDD | 2024-09-03 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2024 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Lohberger (CR9) 2018; 51 Chi (CR14) 2009; 56 Xie, Cai (CR25) 2003; 3 Bogdanov, Moiseenko, Dubina (CR31) 2017; 6 Zhang (CR4) 2016; 502 Kobuke (CR29) 2021 Lingrel, Kuntzweiler (CR21) 1994; 269 CR10 David, Wolfender, Dias (CR1) 2015; 14 Horn (CR15) 2018; 9 Bejcek, Spiwok, Kmonickova, Rimpelova (CR33) 2021; 26 Yang (CR5) 2021; 21 Ran (CR16) 2013; 8 Chen (CR22) 2006; 96 Han (CR8) 2010; 76 Aperia, Akkuratov, Fontana, Brismar (CR26) 2016; 310 Dutta (CR28) 2014; 21 Rajasekaran (CR23) 2004; 15 Feng (CR19) 2023; 14 Chen, Sawyers, Scher (CR11) 2008; 8 CR3 Zhang, Bilic, Troxler, Hess (CR18) 2017; 228 Zhang (CR2) 2016; 105 Walczak, Carducci (CR12) 2007; 82 Sakai (CR24) 2004; 563 Abd Wahab, Lajis, Abas, Othman, Naidu (CR13) 2020 Hu (CR6) 2021; 40 Zhang (CR32) 2017; 14 Zhang, Bilic, Marek, Glosmann, Hess (CR17) 2016; 11 Lingrel, Williams, Vorhees, Moseley (CR27) 2007; 39 Williams (CR30) 2014; 63 Ye (CR7) 2020; 16 Ye (CR20) 2020; 16 71722_CR3 M Horn (71722_CR15) 2018; 9 Y Yang (71722_CR5) 2021; 21 D Zhang (71722_CR32) 2017; 14 SA Rajasekaran (71722_CR23) 2004; 15 N Han (71722_CR8) 2010; 76 JR Walczak (71722_CR12) 2007; 82 NA Abd Wahab (71722_CR13) 2020 RK Dutta (71722_CR28) 2014; 21 W-J Zhang (71722_CR2) 2016; 105 H Sakai (71722_CR24) 2004; 563 H Ye (71722_CR20) 2020; 16 H Ye (71722_CR7) 2020; 16 71722_CR10 A Bogdanov (71722_CR31) 2017; 6 Y Hu (71722_CR6) 2021; 40 J Feng (71722_CR19) 2023; 14 FA Ran (71722_CR16) 2013; 8 JB Lingrel (71722_CR27) 2007; 39 K Kobuke (71722_CR29) 2021 A Aperia (71722_CR26) 2016; 310 Z Xie (71722_CR25) 2003; 3 H-Y Zhang (71722_CR4) 2016; 502 B David (71722_CR1) 2015; 14 B Lohberger (71722_CR9) 2018; 51 J Bejcek (71722_CR33) 2021; 26 X Zhang (71722_CR17) 2016; 11 TA Williams (71722_CR30) 2014; 63 X Zhang (71722_CR18) 2017; 228 JQ Chen (71722_CR22) 2006; 96 Y Chen (71722_CR11) 2008; 8 KN Chi (71722_CR14) 2009; 56 JB Lingrel (71722_CR21) 1994; 269 |
| References_xml | – volume: 96 start-page: 1 year: 2006 end-page: 15 ident: CR22 article-title: Sodium/potassium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides: A new paradigm for development of anti- breast cancer drugs? publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-005-9053-3 – volume: 269 start-page: 19659 year: 1994 end-page: 19662 ident: CR21 article-title: Na+, K(+)-ATPase publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(17)32067-7 – volume: 15 start-page: 3224 year: 2004 end-page: 3232 ident: CR23 article-title: Na, K-ATPase beta1-subunit increases the translation efficiency of the alpha1-subunit in MSV-MDCK cells publication-title: Mol. Biol. Cell doi: 10.1091/mbc.e04-03-0222 – volume: 14 start-page: e0334922 year: 2023 ident: CR19 article-title: N(6)-Methyladenosine and reader protein YTHDF2 enhance the innate immune response by mediating DUSP1 mRNA degradation and activating mitogen-activated protein kinases during bacterial and viral infections publication-title: mBio doi: 10.1128/mbio.03349-22 – volume: 82 start-page: 243 year: 2007 end-page: 249 ident: CR12 article-title: Prostate cancer: A practical approach to current management of recurrent disease publication-title: Mayo Clin. Proc. doi: 10.4065/82.2.243 – volume: 26 start-page: 1905 year: 2021 ident: CR33 article-title: Na(+)/K(+)-ATPase revisited: On its mechanism of action, role in cancer, and activity modulation publication-title: Molecules doi: 10.3390/molecules26071905 – ident: CR10 – volume: 9 start-page: 9838 year: 2018 end-page: 9851 ident: CR15 article-title: Unbiased compound-protein interface mapping and prediction of chemoresistance loci through forward genetics in haploid stem cells publication-title: Oncotarget doi: 10.18632/oncotarget.24305 – volume: 16 start-page: 1406 year: 2020 end-page: 1415 ident: CR7 article-title: Mechanism of action of periplogenin on nasopharyngeal carcinoma based on network pharmacology and experimental study of vitamin E coupled with periplogenin self-assembled nano-prodrug for nasopharyngeal carcinoma publication-title: J. Biomed. Nanotechnol. doi: 10.1166/jbn.2020.2978 – volume: 63 start-page: 188 year: 2014 end-page: 195 ident: CR30 article-title: Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.113.01733 – volume: 21 start-page: L1 year: 2014 end-page: 4 ident: CR28 article-title: Complementary somatic mutations of KCNJ5, ATP1A1, and ATP2B3 in sporadic aldosterone producing adrenal adenomas publication-title: Endocr. Relat. Cancer doi: 10.1530/ERC-13-0466 – volume: 14 start-page: 15 year: 2017 ident: CR32 article-title: Downregulation of ATP1A1 promotes cancer development in renal cell carcinoma publication-title: Clin. Proteom. doi: 10.1186/s12014-017-9150-4 – volume: 21 start-page: 61 year: 2021 end-page: 70 ident: CR5 article-title: Periplogenin activates ROS-ER stress pathway to trigger apoptosis via BIP-eIF2α-CHOP and IRE1α-ASK1-JNK signaling routes publication-title: Anti-Cancer Agents Med. Chem. doi: 10.2174/1871520620666200708104559 – volume: 6 start-page: 10 year: 2017 ident: CR31 article-title: Abnormal expression of ATP1A1 and ATP1A2 in breast cancer publication-title: F1000Res. doi: 10.12688/f1000research.10481.1 – volume: 310 start-page: C491 year: 2016 end-page: C495 ident: CR26 article-title: Na+-K+-ATPase, a new class of plasma membrane receptors publication-title: Am. J. Physiol. Cell Physiol. doi: 10.1152/ajpcell.00359.2015 – volume: 51 start-page: 162 year: 2018 end-page: 170 ident: CR9 article-title: Periplocin, the most anti-proliferative constituent of , specifically kills liposarcoma cells by death receptor mediated apoptosis publication-title: Phytomedicine doi: 10.1016/j.phymed.2018.10.008 – volume: 39 start-page: 385 year: 2007 end-page: 389 ident: CR27 article-title: Na, K-ATPase and the role of alpha isoforms in behavior publication-title: J. Bioenerg. Biomembr. doi: 10.1007/s10863-007-9107-9 – volume: 502 start-page: 98 year: 2016 end-page: 106 ident: CR4 article-title: Tumor targeted delivery of octreotide-periplogenin conjugate: Synthesis, in vitro and in vivo evaluation publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2016.02.024 – volume: 76 start-page: 561 year: 2010 end-page: 565 ident: CR8 article-title: Inhibitory activity of a phytochemically characterized fraction from on lung cancer in nude mice publication-title: Planta Med. doi: 10.1055/s-0029-1240600 – year: 2020 ident: CR13 article-title: Mechanism of anti-cancer activity of curcumin on androgen-dependent and androgen-independent prostate cancer publication-title: Nutrients doi: 10.3390/nu12030679 – volume: 228 start-page: 75 year: 2017 end-page: 78 ident: CR18 article-title: Evidence of genotypes 1 and 3 of avian hepatitis E virus in wild birds publication-title: Virus Res. doi: 10.1016/j.virusres.2016.11.028 – volume: 8 start-page: 2281 year: 2013 end-page: 2308 ident: CR16 article-title: Genome engineering using the CRISPR-Cas9 system publication-title: Nat. Protoc. doi: 10.1038/nprot.2013.143 – ident: CR3 – year: 2021 ident: CR29 article-title: ATP1A1 mutant in aldosterone-producing adenoma leads to cell proliferation publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms222010981 – volume: 40 start-page: 3942 year: 2021 end-page: 3958 ident: CR6 article-title: Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3 publication-title: Oncogene doi: 10.1038/s41388-021-01817-2 – volume: 563 start-page: 151 year: 2004 end-page: 154 ident: CR24 article-title: Up-regulation of Na(+), K(+)-ATPase alpha 3-isoform and down-regulation of the alpha1-isoform in human colorectal cancer publication-title: FEBS Lett. doi: 10.1016/S0014-5793(04)00292-3 – volume: 105 start-page: 66 year: 2016 end-page: 79 ident: CR2 article-title: Periplogenin induces necroptotic cell death through oxidative stress in HaCaT cells and ameliorates skin lesions in the TPA-and IMQ-induced psoriasis-like mouse models publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2016.02.001 – volume: 14 start-page: 299 year: 2015 end-page: 315 ident: CR1 article-title: The pharmaceutical industry and natural products: Historical status and new trends publication-title: Phytochem. Rev. doi: 10.1007/s11101-014-9367-z – volume: 3 start-page: 157 year: 2003 ident: CR25 article-title: Na+-K+–ATPase-mediated signal transduction: From protein interaction to cellular function publication-title: Mol. Interv. doi: 10.1124/mi.3.3.157 – volume: 56 start-page: 594 year: 2009 end-page: 605 ident: CR14 article-title: Castration-resistant prostate cancer: From new pathophysiology to new treatment targets publication-title: Eur. Urol. doi: 10.1016/j.eururo.2009.06.027 – volume: 8 start-page: 440 year: 2008 end-page: 448 ident: CR11 article-title: Targeting the androgen receptor pathway in prostate cancer publication-title: Curr. Opin. Pharmacol. doi: 10.1016/j.coph.2008.07.005 – volume: 11 start-page: e0153723 year: 2016 ident: CR17 article-title: C-terminal amino acids 471–507 of avian hepatitis E virus capsid protein are crucial for binding to avian and human cells publication-title: PLoS ONE doi: 10.1371/journal.pone.0153723 – volume: 16 start-page: 1406 year: 2020 end-page: 1415 ident: CR20 article-title: Mechanism of action of periplogenin on nasopharyngeal carcinoma based on network pharmacology and experimental study of vitamin E coupled with periplogenin self-assembled nano-prodrug for nasopharyngeal carcinoma publication-title: J. Biomed. Nanotechnol. doi: 10.1166/jbn.2020.2978 – ident: 71722_CR3 – volume: 76 start-page: 561 year: 2010 ident: 71722_CR8 publication-title: Planta Med. doi: 10.1055/s-0029-1240600 – volume: 11 start-page: e0153723 year: 2016 ident: 71722_CR17 publication-title: PLoS ONE doi: 10.1371/journal.pone.0153723 – ident: 71722_CR10 doi: 10.21037/amj.2018.12.07 – volume: 8 start-page: 2281 year: 2013 ident: 71722_CR16 publication-title: Nat. Protoc. doi: 10.1038/nprot.2013.143 – volume: 26 start-page: 1905 year: 2021 ident: 71722_CR33 publication-title: Molecules doi: 10.3390/molecules26071905 – volume: 310 start-page: C491 year: 2016 ident: 71722_CR26 publication-title: Am. J. Physiol. Cell Physiol. doi: 10.1152/ajpcell.00359.2015 – volume: 14 start-page: e0334922 year: 2023 ident: 71722_CR19 publication-title: mBio doi: 10.1128/mbio.03349-22 – volume: 51 start-page: 162 year: 2018 ident: 71722_CR9 publication-title: Phytomedicine doi: 10.1016/j.phymed.2018.10.008 – volume: 9 start-page: 9838 year: 2018 ident: 71722_CR15 publication-title: Oncotarget doi: 10.18632/oncotarget.24305 – volume: 21 start-page: 61 year: 2021 ident: 71722_CR5 publication-title: Anti-Cancer Agents Med. Chem. doi: 10.2174/1871520620666200708104559 – volume: 563 start-page: 151 year: 2004 ident: 71722_CR24 publication-title: FEBS Lett. doi: 10.1016/S0014-5793(04)00292-3 – volume: 3 start-page: 157 year: 2003 ident: 71722_CR25 publication-title: Mol. Interv. doi: 10.1124/mi.3.3.157 – volume: 21 start-page: L1 year: 2014 ident: 71722_CR28 publication-title: Endocr. Relat. Cancer doi: 10.1530/ERC-13-0466 – volume: 40 start-page: 3942 year: 2021 ident: 71722_CR6 publication-title: Oncogene doi: 10.1038/s41388-021-01817-2 – volume: 14 start-page: 299 year: 2015 ident: 71722_CR1 publication-title: Phytochem. Rev. doi: 10.1007/s11101-014-9367-z – volume: 228 start-page: 75 year: 2017 ident: 71722_CR18 publication-title: Virus Res. doi: 10.1016/j.virusres.2016.11.028 – volume: 105 start-page: 66 year: 2016 ident: 71722_CR2 publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2016.02.001 – volume: 16 start-page: 1406 year: 2020 ident: 71722_CR20 publication-title: J. Biomed. Nanotechnol. doi: 10.1166/jbn.2020.2978 – volume: 39 start-page: 385 year: 2007 ident: 71722_CR27 publication-title: J. Bioenerg. Biomembr. doi: 10.1007/s10863-007-9107-9 – volume: 56 start-page: 594 year: 2009 ident: 71722_CR14 publication-title: Eur. Urol. doi: 10.1016/j.eururo.2009.06.027 – volume: 269 start-page: 19659 year: 1994 ident: 71722_CR21 publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(17)32067-7 – volume: 8 start-page: 440 year: 2008 ident: 71722_CR11 publication-title: Curr. Opin. Pharmacol. doi: 10.1016/j.coph.2008.07.005 – volume: 82 start-page: 243 year: 2007 ident: 71722_CR12 publication-title: Mayo Clin. Proc. doi: 10.4065/82.2.243 – volume: 16 start-page: 1406 year: 2020 ident: 71722_CR7 publication-title: J. Biomed. Nanotechnol. doi: 10.1166/jbn.2020.2978 – volume: 14 start-page: 15 year: 2017 ident: 71722_CR32 publication-title: Clin. Proteom. doi: 10.1186/s12014-017-9150-4 – volume: 63 start-page: 188 year: 2014 ident: 71722_CR30 publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.113.01733 – volume: 15 start-page: 3224 year: 2004 ident: 71722_CR23 publication-title: Mol. Biol. Cell doi: 10.1091/mbc.e04-03-0222 – year: 2020 ident: 71722_CR13 publication-title: Nutrients doi: 10.3390/nu12030679 – volume: 502 start-page: 98 year: 2016 ident: 71722_CR4 publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2016.02.024 – volume: 96 start-page: 1 year: 2006 ident: 71722_CR22 publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-005-9053-3 – year: 2021 ident: 71722_CR29 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms222010981 – volume: 6 start-page: 10 year: 2017 ident: 71722_CR31 publication-title: F1000Res. doi: 10.12688/f1000research.10481.1 |
| SSID | ssj0000529419 |
| Score | 2.4515347 |
| Snippet | Natural compounds constitute a major resource for the development of medicines for multiple diseases. While many natural compounds show strong biological... Abstract Natural compounds constitute a major resource for the development of medicines for multiple diseases. While many natural compounds show strong... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 20509 |
| SubjectTerms | 631/154 631/67 Amino acid substitution Amino acids Animals Antineoplastic Agents - pharmacology Antitumor agents Biological activity Cell Line, Tumor Cell Proliferation - drug effects Cytotoxicity Genetic screening Humanities and Social Sciences Humans Male Mice Mode of action multidisciplinary Mutagenesis Na+/K+-exchanging ATPase Next-generation sequencing Prostate cancer Prostate carcinoma Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Science Science (multidisciplinary) Sodium-Potassium-Exchanging ATPase - genetics Sodium-Potassium-Exchanging ATPase - metabolism Therapeutic targets Tumor cell lines Tumors Xenograft Model Antitumor Assays Xenografts |
| SummonAdditionalLinks | – databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaggNQLb0qgICNxg6ixncTOCS2IigOq9lBQb5ZjO-1KbRI2u0j775lxvKmWRy9c17OSnRnPwzPzDSFvwWIIlxmVOl7LNC-9TavCgTLktjZl3qgsTGv4_lWenKizs2oeH9yGWFa51YlBUbvO4hv5ET5ECzDesvzQ_0hxahRmV-MIjdvkDqIkiFC6N5_eWDCLlbMq9spkQh0NYK-wp4xjEaKEOEzu2KMA2_83X_PPksnf8qbBHB0_-N-DPCT3oyNKZ6PkPCK3fPuY3BtHU26ekB7khwbUTyDCunMcv0QRFrkHAt8uWjqs-1BF6wcKXiQ9h4B-dUG7hvbYSQI-LLU4qKjtrgzF_MBA6w0dTejlho4l6HA2Ojudsxl7Sr4dfz799CWN0xlSW-RsleYenC1XWETQy2pWS26dyUshnSyMyRtrZeVqXluO_faltcAN6UrHPQZJxohnZK_tWv-cUFspoyxEjs4UucPEpikqZ6xzTQMRdJEQtuWRthG6HCdoXOqQQhdKj3zVwFcd-KplQt5N_-lH4I4bqT8i6ydKBN0OP3TLcx3vsJbOg_aqHTOYTlawWSXrMlOVqQRrnE3I4ZbjOmqCQV-zOyFvpmW4w_jhTeu79UhTYK8m0ByMcjbtBPxXDi46rKgdCdzZ6u5Ku7gIOOGMCYjvRZaQ91thvd7Xv7_Fi5uP8ZLsc7w_mFQTh2RvtVz7V-Su_blaDMvX4QL-AobJOLM priority: 102 providerName: ProQuest |
| Title | The natural compound periplogenin suppresses the growth of prostate carcinoma cells by directly targeting ATP1A1 |
| URI | https://link.springer.com/article/10.1038/s41598-024-71722-7 https://www.ncbi.nlm.nih.gov/pubmed/39227746 https://www.proquest.com/docview/3100364476 https://www.proquest.com/docview/3100561786 https://pubmed.ncbi.nlm.nih.gov/PMC11372130 https://doaj.org/article/7de794bd1a30468da587b6089a931fdc |
| Volume | 14 |
| WOSCitedRecordID | wos001305757100017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgA4kXxDeBURmJN4gW20nsPHZoE0isitBA5clybGerNNJqaZH633Nnp2Xl84UXP8QXybo75-5yd78j5BVYDOEyo1LHG5nmpbdpVTj4GHLbmDJvVRamNXz-ICcTNZ1W9bVRX1gTFuGBI-MOpfOgMo1jBnN4yplCyabMVGUqwVpn8esLXs-1YCqievMqZ9XQJZMJddiDpcJuMo7lhxIiMLljiQJg_--8zF-LJX_KmAZDdHKP3B08SDqOJ79PbvjuAbkdZ0quH5IFCJ4GuE4gwoJxnJtEEc94AQS-m3W0Xy1C-avvKbh_9Bwi8eUFnbd0gS0g4HxSixOGuvlXQ_HHfk-bNY2273JNY-04HI2Oz2o2Zo_Ip5Pjs7fv0mGsQmqLnC3T3IOX5AqL0HdZwxrJrTN5KaSThTF5a62sXMMby7FRvrQWmCld6bjH6MYY8ZjsdfPOPyXUVsooCyEfiCV3mJE0ReWMda5tIfQtEsI2LNZ2wBzH0ReXOuS-hdJRLBrEooNYtEzI6-07i4i48VfqI5TclhLRssMD0CE96JD-lw4l5GAjdz1c4V5j5kOAtyjLhLzcbsPlQ8abzs9XkabAJkugeRLVZHsScDw5-Nawo3YUaOeouzvd7CIAfDMmIDAXWULebHTtx7n-zItn_4MXz8kdjpcEc2bigOwtr1b-Bbllvy1n_dWI3JRTGVY1IvtHx5P64yjcPFhPeY2rhHW_fn9af_kONcIx4g |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKAcGFHTpQwEhwgqiJs9g5IDQsVasOozkMqDfj2E47UpuEyQzV_Cl-I-85SzUsvfXANX4TOZ7vPX_22wh5CTtGaHwlPMMy7kWJ1V4aGzCGTGcqiXLhu24NX0d8PBaHh-lkg_zscmEwrLKzic5Qm1LjHfkOXkSHsHnz5F313cOuUehd7VpoNLA4sKszOLLVb_c_wv_7irHdT9MPe17bVcDTcRQsvMgCSTCxxspvfhZknGmjoiTkhsdKRbnWPDUZyzTDPPFEaz9m3CSGWST3SoXw3ivkKtAIJlyo4KS_00GvWRSkbW6OH4qdGvZHzGFjGPTI4dzH1_Y_1ybgb9z2zxDN3_y0bvvbvf2_Ldwdcqsl2nTYaMZdsmGLe-R603pzdZ9UoB_UVTUFIYyrx_ZSFMs-VyBgi1lB62XlooRtTYEl06N5ebY4pmVOK8yUAY5ONTZiKspTRdH_UdNsRRuKcLKiTYg9rCUdTifBMHhAvlzK5z4km0VZ2C1CdSqU0HAyNiqODDpuVZwapY3J8xAo8IAEHSakbkuzY4eQE-lCBEIhGxxJwJF0OJJ8QF73v6mawiQXSr9HqPWSWFTcPSjnR7K1UZIbC9Y5M4FCd7mAyQqeJb5IVRoGudEDst0hTLaWrpbn8BqQF_0w2ChceFXYctnIxJiLCjKPGlz3MwF-zuAIAiNiDfFrU10fKWbHrg56EIScAQcbkDedcpzP699r8fjiz3hObuxNP4_kaH988ITcZKi76EAMt8nmYr60T8k1_WMxq-fPnPJT8u2yleYXtNCVsA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKWcSFnTJQwEhwgmgSZ7FzQGigjKhajeZQUG-uYzvtSG0SJjNU89f4dbznLNWw9NYD1_hN5Hi-9_zZbyPkNewYofGV8AzLuBclVntpbMAYMp2pJMqF77o1fNvnk4k4PEynG-RnlwuDYZWdTXSG2pQa78iHeBEdwubNk2HehkVMd8Yfqu8edpBCT2vXTqOByJ5dncPxrX6_uwP_9RvGxp8PPn3x2g4Dno6jYOFFFgiDiTVWgfOzIONMGxUlITc8VirKteapyVimGeaMJ1r7MeMmMcwi0VcqhPdeI9c5Fi13YYPT_n4HPWhRkLZ5On4ohjXslZjPxjAAksMZkK_tha5lwN947p_hmr_5bN1WOL77Py_iPXKnJeB01GjMfbJhiwfkZtOSc_WQVKA31FU7BSGMt8e2UxTLQVcgYItZQetl5aKHbU2BPdPjeXm-OKFlTivMoAHuTjU2aCrKM0XRL1LTbEUb6nC6ok3oPawrHR1Mg1HwiHy9ks99TDaLsrBPCNWpUELDidmoODLo0FVxapQ2Js9DoMYDEnT4kLot2Y6dQ06lCx0IhWwwJQFT0mFK8gF52_-magqWXCr9EWHXS2KxcfegnB_L1nZJbixY7cwECt3oAiYreJb4IlVpGORGD8h2hzbZWsBaXkBtQF71w2C7cOFVYctlIxNjjirIbDUY72cCvJ3B0QRGxBr616a6PlLMTlx99CAIOQNuNiDvOkW5mNe_1-Lp5Z_xktwCXZH7u5O9Z-Q2QzVGv2K4TTYX86V9Tm7oH4tZPX_h7AAlR1etM78Ai3KebQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+natural+compound+periplogenin+suppresses+the+growth+of+prostate+carcinoma+cells+by+directly+targeting+ATP1A1&rft.jtitle=Scientific+reports&rft.au=Xinquan+Zhang&rft.au=Tinglin+Pang&rft.au=Haifeng+Zhang&rft.au=Moritz+Horn&rft.date=2024-09-03&rft.pub=Nature+Portfolio&rft.eissn=2045-2322&rft.volume=14&rft.issue=1&rft.spage=1&rft.epage=8&rft_id=info:doi/10.1038%2Fs41598-024-71722-7&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_7de794bd1a30468da587b6089a931fdc |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |